Succinylacetone

Succinylacetone

SCHEMBL503918

CC(=O)CC(=O)CCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 7/20 1.00
KDM2A Q9Y2K7 7/20 1.00
EGLN1 Q9GZT9 5/20 1.00
KDM4E B2RXH2 4/20 1.00
KDM5C P41229 4/20 1.00
KDM6B O15054 2/20 1.00
LMNA P02545 3/20 0.60
SLC15A2 Q16348 1/20 0.60
GABRR1 P24046 1/20 0.55
ALKBH5 Q6P6C2 1/20 0.50
SUCNR1 Q9BXA5 1/20 0.50
ACE P12821 1/20 0.46
FOLH1 Q04609 1/20 0.42
FFAR3 O14843 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
KDM7A Q6ZMT4 1/20 0.41
ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9839290 0.95 PHF8 (0.90) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL61062 0.88 KDM4E (0.78) PHF8KDM2AEGLN1KDM4EKDM5C
Succinylacetone SCHEMBL29120445 0.87 PHF8 (0.75) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL15148024 0.84 KDM4E (0.73) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL515966 0.84 KDM4E (0.73) PHF8KDM2AEGLN1KDM4EKDM5C
Acetic Acid SCHEMBL30309106 0.83 PHF8 (0.71) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL7016070 0.82 KDM4E (0.70) PHF8KDM2AEGLN1KDM4EKDM5C
Succinic Acid SCHEMBL8382879 0.82 PHF8 (0.70) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL6027524 0.82 KDM4E (0.70) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL4098641 0.82 PHF8 (0.68) PHF8KDM2AEGLN1KDM4EKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
US-20250073321-A1 Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders UNIV NEW YORK (US) 2025-03-06 US claimed
EP-4509174-A2 COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH The Regents of the University of California (US) 2025-02-19 EP claimed
US-12162977-B2 Blocked polyisocyanate crosslinking agent, its preparation method and a coating composition comprising the same BASF COATINGS GMBH (DE) 2024-12-10 US claimed
EP-3411011-B1 COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH UNIV CALIFORNIA (US) 2024-09-18 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-114729100-B Blocked polyisocyanate crosslinking agent, process for producing the same and coating composition comprising the same 巴斯夫涂料有限公司 2024-04-16 CN claimed
US-20220389153-A1 A BLOCKED POLYISOCYANATE CROSSLINKING AGENT, ITS PREPARATION METHOD AND A COATING COMPOSITION COMPRISING THE SAME BASF COATINGS GMBH (DE) 2022-12-08 US claimed
EP-4058500-A1 A BLOCKED POLYISOCYANATE CROSSLINKING AGENT, ITS PREPARATION METHOD AND A COATING COMPOSITION COMPRISING THE SAME BASF Coatings GmbH (DE) 2022-09-21 EP claimed
CN-114729100-A Blocked polyisocyanate crosslinkers, process for their preparation and coating compositions comprising the crosslinkers 巴斯夫涂料有限公司 2022-07-08 CN claimed
US-7074770-B1 Method of DNA vaccination SMITHKLINE BEECHAM CORPORATION (US) 2006-07-11 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-6573245-B1 Conjugate including polysaccharide which binds to cell surface of Antigen Presenting Cell, protein or peptide antigen which elicits immunogenic response when covalently attached to polysaccharide, imine-forming compound GALENICA PHARMACEUTICALS, INC. 2003-06-03 US claimed
EP-1107785-A1 METHOD OF DNA VACCINATION GLAXO GROUP LIMITED (GB) 2001-06-20 EP claimed
WO-2000012121-A1 METHOD OF DNA VACCINATION GLAXO GROUP LIMITED (GB) 2000-03-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 PHF8 2309/4885KDM2A 1765/4885EGLN1 4717/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 PHF8 1523/4885KDM2A 1744/4885EGLN1 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.